The present study was undertaken to investigate the effects of prolactin (PRL) on gonadotropin-induced ovulation and the biosynthesis of prostaglandin (PG), leukotriene (LT), and plasmin in in vitro perfused rabbit ovaries. The addition of PRL to the perfusate inhibited hCG-induced ovulation in vitro in a dose-dependent manner. Although exposure to hCG significantly increased PGF2 alpha, PGE2, and LTB4 production by perfused rabbit ovaries, PRL did not affect the secretion rates of PGs and LTB4 stimulated by hCG administration. The ovarian plasmin generation was determined by measuring the amount of plasmin bound to its major inhibitor, alpha 2-plasmin inhibitor (alpha 2PI-Plm). Exposure to hCG enhanced biphasically the ovarian secretion rate of alpha 2 PI-Plm, while PRL at a dose of 10(3) ng/ml significantly inhibited the hCG-stimulated generation of alpha 2 PI-Plm in ovaries throughout the entire perfusion period. A significant correlation was observed between ovulatory efficiency and ovarian plasmin generation in the PRL-treated ovaries. Additionally, PRL inhibited intrafollicular concentrations of alpha 2 PI-Plm in hCG-treated ovaries in a dose-dependent manner. These observations substantiate an essential role for a plasma-generating system in the cascade of events leading to ovulation. In conclusion, PRL may act directly on the ovary and block ovulation, at least in part, via the inhibition of ovarian plasmin generation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1095/biolreprod50.6.1223 | DOI Listing |
J Obstet Gynaecol Res
November 2023
Department of Gynecology and Reproductive Medicine, Ms.Clinic MayOne, Kashihara, Japan.
Aim: Tissue factor pathway inhibitor 2 (TFPI2) is a structural homolog of tissue factor pathway inhibitor 1 (TFPI1). Since TFPI2 is a placenta-derived protein, dynamic changes in TFPI2 levels may be related to pregnancy-related diseases. Furthermore, TFPI2 has been reported to be a novel serum biomarker for detecting ovarian cancer, especially clear cell carcinoma (CCC).
View Article and Find Full Text PDFJ Obstet Gynaecol Res
July 2023
Department of Gynecology, Ms.Clinic MayOne, Kashihara, Japan.
Aim: Tissue factor (TF), the primary initiator of the extrinsic coagulation pathway, contributes to the generation of a hypercoagulable and prothrombotic state in cancer patients. TF pathway inhibitor (TFPI) is a major inhibitor of TF-mediated coagulation pathway. The two proteins, TFPI1 and TFPI2, are encoded by separate genes.
View Article and Find Full Text PDFInt J Mol Sci
October 2022
Graduate School of Fisheries Sciences, Hokkaido University, Hakodate 041-8611, Hokkaido, Japan.
The luteinizing hormone (LH) and maturation-inducing steroids (MIS), such as 17α,20β-dihydroxy-4-pregnen-3-one, regulate the final oocyte maturation in teleosts. Oocyte maturational competence (OMC) and ovulatory competence measure the sensitivity to MIS for oocyte maturation and ovulation, respectively. However, the molecular mechanisms underlying the acquisition of ovulatory competence remain unknown.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2021
Department of Clinical Laboratory, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Accurate diagnosis and classification of ovarian hyperstimulation syndrome (OHSS) is important for its management. We employed a new high-sensitivity chemiluminescence immunoassay to detect the thrombin-antithrombin complex (TAT), plasmin alpha2-plasmin inhibitor complex (PIC), soluble thrombomodulin (sTM), and tissue plasminogen activator-inhibitor complex (TPAI-C), and evaluated their diagnostic and classification performance for OHSS. A total of 106 women were enrolled, including 51 patients with OHSS (25 mild or moderate OHSS, 26 severe OHSS), and 55 without OHSS (control group).
View Article and Find Full Text PDFJ Obstet Gynaecol Res
September 2021
Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara, Japan.
Aims: Tissue factor pathway inhibitor (TFPI)-2 has recently emerged as a serodiagnostic marker for patients with epithelial ovarian cancer (EOC), especially clear cell carcinoma (CCC). This review discusses the biological properties of TFPI-2 and why serum levels are elevated in CCC patients.
Methods: A comprehensive literature search was conducted in PubMed up until March, 2021.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!